L3VLUP
ProSign in

GEHC · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

GEHCVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • GEHC
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterGEHCVRTX
Q3 2020none listed holders, n.a.31 holders, $21.9bn
Q4 2020none listed holders, n.a.30 holders, $18.4bn
Q1 2021none listed holders, n.a.31 holders, $15.4bn
Q2 2021none listed holders, n.a.30 holders, $12.7bn
Q3 2021none listed holders, n.a.35 holders, $10.1bn
Q4 2021none listed holders, n.a.28 holders, $12.4bn
Q1 2022none listed holders, n.a.23 holders, $16.1bn
Q2 2022none listed holders, n.a.25 holders, $18.1bn
Q3 2022none listed holders, n.a.22 holders, $18.4bn
Q4 20221 holders, $371m28 holders, $18.4bn
Q1 202313 holders, $8.0bn26 holders, $21.4bn
Q2 202321 holders, $8.7bn27 holders, $24.7bn
Q3 202314 holders, $6.6bn33 holders, $24.3bn
Q4 202313 holders, $7.3bn32 holders, $28.6bn
Q1 202417 holders, $9.7bn31 holders, $29.8bn
Q2 202417 holders, $8.0bn29 holders, $33.4bn
Q3 202420 holders, $10.7bn27 holders, $33.5bn
Q4 202418 holders, $8.8bn26 holders, $28.5bn
Q1 202518 holders, $8.4bn21 holders, $35.4bn
Q2 202522 holders, $7.2bn21 holders, $32.3bn
Q3 202514 holders, $6.3bn22 holders, $25.9bn
Q4 202513 holders, $8.1bn26 holders, $31.8bn
Q1 202611 holders, $6.3bn25 holders, $31.8bn
Q2 20269 holders, $4.9bn26 holders, $34.6bn
GEHC

Ge Healthcare Technologies I

Holders
13
Reported value
$8.1bn
Buyers
17
Sellers
22

Breadth -5 among 92 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
VRTX

Vertex Pharmaceuticals Inc

Holders
26
Reported value
$31.8bn
Buyers
19
Sellers
20

Breadth -1 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2025

Among the 35 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only GEHC (9)

D. E. Shaw & Co., D1 Capital Partners LP, Dodge & Cox, Farallon Capital Management LLC, First Eagle Investment Management LLC, Harris Associates LP, Holocene Advisors LP, Soros Fund Management LLC, Trian Fund Management LP

Only VRTX (22)

Acadian Asset Management LLC, ARK Investment Management LLC, Arrowstreet Capital LP, Baillie Gifford & Co, Balyasny Asset Management LLC, Bridgewater Associates LP, Capital World Investors, Citadel Advisors LLC, Fidelity (FMR LLC), Hudson Bay Capital Management LP, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, Millennium Management LLC, Neuberger Berman Group LLC, Renaissance Technologies LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP, Wellington Management Group LLP, Winton Group Ltd, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →